Covered recipient · General Payments record
CHARLES SHARP
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2019–2025
$2,676.06
- Reported across 153 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $273.60 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SHIELD THERAPEUTICS INC | $53.34 | 3 |
| Astellas Pharma US Inc | $38.31 | 2 |
| ABBVIE INC. | $38.07 | 2 |
| Amgen Inc. | $29.02 | 2 |
| Lilly USA, LLC | $21.48 | 1 |
| Meditrina | $21.18 | 1 |
| Hologic Sales and Service, LLC | $20.28 | 1 |
| Novo Nordisk AS | $19.08 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.01 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $14.83 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.55 | 01/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204224170 | CMS |
| ABBVIE INC. | $14.52 | 04/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204224176 | CMS |
| Amgen Inc. | $14.31 | 08/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227090115 | CMS |
| Amgen Inc. | $14.71 | 10/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227090113 | CMS |
| Astellas Pharma US Inc | $17.12 | 08/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238652930 | CMS |
| Astellas Pharma US Inc | $21.19 | 11/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238628699 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.01 | 08/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1225791998 | CMS |
| Hologic Sales and Service, LLC | $20.28 | 01/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1182511717 | CMS |
| Lilly USA, LLC | $21.48 | 02/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186487419 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $14.83 | 05/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254316828 | CMS |
| Meditrina | $21.18 | 05/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254893728 | CMS |
| Novo Nordisk Inc | $19.08 | 10/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188761244 | CMS |
| SHIELD THERAPEUTICS INC | $18.82 | 03/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249610028 | CMS |
| SHIELD THERAPEUTICS INC | $14.62 | 07/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249620518 | CMS |
| SHIELD THERAPEUTICS INC | $19.90 | 10/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249626456 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.